ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
AbCellera Biologics Inc. (ABCL) stock surged +1.36%, trading at $2.23 on NASDAQ, up from the previous close of $2.20. The stock opened at $2.22, fluctuating between $2.11 and $2.24 in the recent session.
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Employees | 596 |
Beta | 0.45 |
Sales or Revenue | $38.03M |
5Y Sales Change% | 2.54% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |